Stress Response and Sleep Changes is the main area connected here, and any felt benefit should be read together with the human evidence base.
Some human supplement-context evidence is present and directly informs the score.
Representative tier calculated from paper evidence that passed the collection audit.
The representative ingredient tier is calculated from these target-level evidence groups.
These findings come from stress response, cortisol, anxiety, or sleep outcomes. They may mix felt benefits with physiological markers.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
This range includes studies in specific patient groups. It is not a general dose or recommendation.
Findings from studies of this ingredient alone are separated from findings involving another supplement or medication.
No standalone side-effect or combination signal is currently clear enough to show from the collected papers. This does not mean there is no concern.
Paper IDs and full lists are private. Only study types and summaries are shown.
[Abstract]: This review assesses the parallel data on the role of gamma‐aminobutyric acid (GABA) in depression and anxiety. We review historical and new data from both animal and human experimentation which have helped define the key role for this transmitter
This updated review was mainly focused to describe the pharmaceutical properties of Gaba as well as emphasize its important role regarding human health.
Findings support a role for GABA in the generation and modulation of endogenous motor cortex rhythmic beta and gamma activity and suggest that older participants had a lower gamma frequency.
Although more studies are needed before any inferences can be made about the efficacy of oral GABA consumption on stress and sleep, results show that there is limited evidence for stress and verylimited evidence for sleep benefits of oral GABA intake.
[Abstract]: Activation of the metabotropic gamma-aminobutyric acid(B) (GABA(B)) receptor increases K(+) conductance and decreases Ca(2+) channel activity in neuronal membranes. Studies with a number of new GABA(B) receptor agonists and antagonists reveal that
Novel findings from a large, healthy, older population indicate that cognitive function is sensitive to cerebral GABA concentrations in the frontal cortex, and GABA concentration in frontal and posterior regions continue to decline in later age.